Prajwal Gowda Padamane Ranganatha, Bai J Sarah, Naik Sudhir M, Abhilasha Somashekar
Department of Otorhinolaryngology, The Oxford Medical College, Hospital and RC, Yadavanahalli, Bangalore, Karnataka India.
Indian J Otolaryngol Head Neck Surg. 2023 Dec;75(4):3337-3343. doi: 10.1007/s12070-023-03929-5. Epub 2023 Jun 21.
Sino-Nasal Outcome Test (SNOT-22) symptom score is the most widely used questionnaire due to its easy interpretation with respect to quality of life (QOL) in patients with chronic rhinosinusitis (CRS). It helps in deciding further treatment plan in patients with refractory CRS despite maximal medical therapy (MMT). Endoscopic sinus surgery (ESS) is suggested in patients not responding to medical treatment. The preoperative and post-operative QOL for patients with CRS is assessed using SNOT-22. To assess SNOT-22 score change in CRS resistant to MMT. This is a longitudinal study conducted from April 2021-September 2022 included patients diagnosed to have CRS, satisfying the inclusion criteria. SNOT-22 for symptom severity assessed at the first visit, 1 week and 12 weeks and after MMT. Patients who failed MMT, posted for ESS. Post-operatively SNOT-22 symptom score re-assessed at 15 days, 1 month, 2 months and 3 months. 56 patients (male-51% and female-49%) who failed to respond to MMT included in the study. The five major troublesome symptoms nasal blockage (92.86%), need to blow nose (75%), facial pressure/pain (53.57%), post nasal discharge (51.79%), and sneezing (42.86%). The mean SNOT-22 symptom score when compared with pre-operatively (69.54 ± 8.973) and after FESS (2.09 ± 1.881) had improved significantly ( < 0.001). CRS is more frequently seen in males aged between 21 and 30 years. The patient-based outcome measures, like SNOT-22 helps to foresee the extent of post- operative improvement. The effective management of CRS is by surgical intervention.
鼻窦结局测试（SNOT-22）症状评分是应用最广泛的调查问卷，因为它在解释慢性鼻窦炎（CRS）患者的生活质量（QOL）方面很容易理解。它有助于为尽管接受了最大程度药物治疗（MMT）但仍患有难治性CRS的患者确定进一步的治疗方案。对于药物治疗无反应的患者，建议进行鼻内镜鼻窦手术（ESS）。使用SNOT-22评估CRS患者术前和术后的生活质量。以评估对MMT耐药的CRS患者的SNOT-22评分变化。这是一项从2021年4月至2022年9月进行的纵向研究，纳入了符合纳入标准且被诊断为患有CRS的患者。在首次就诊、1周、12周以及MMT后评估SNOT-22症状严重程度。MMT失败的患者安排进行ESS。术后在15天、1个月、2个月和3个月重新评估SNOT-22症状评分。该研究纳入了56例对MMT无反应的患者（男性占51%，女性占49%）。五个主要的困扰症状为鼻塞（92.86%）、需要擤鼻（75%）、面部压迫感/疼痛（53.57%）、鼻后滴漏（51.79%）和打喷嚏（42.86%）。与术前（69.54±8.973）和功能性内镜鼻窦手术（FESS）后（2.09±1.881）相比，SNOT-22症状评分显著改善（<0.001）。CRS在21至30岁的男性中更为常见。基于患者的结局指标，如SNOT-22有助于预测术后改善程度。CRS的有效管理方法是手术干预。
